Indian pharmaceutical company Zydus Cadila has signed a strategic collaboration agreement with Turkish-based healthcare company Eczacibasi Ilaç Pazarlama, in a bid to commercialise biotech products in the Turkish market.

Under the agreement, the companies will import biosimilars that are at present unavailable in Turkey, especially for the treatment of cancer.

The deal also helps develop a long-term strategic collaboration with an aim to manufacture and launch new products in the country’s market.

Zydus Group chairman and managing director Pankaj Patel said: “We are glad to partner with Eczacibasi, a leading group in the field of healthcare in Turkey, to make available biotech therapies for patients in Turkey.

“The long-term agreement between both partners to enrich this collaboration through introduction of new products will augur well for healthcare access beyond geographies.”

“The long-term agreement between both partners to enrich this collaboration through introduction of new products will augur well for healthcare access beyond geographies.”

Eczacibasi chairman Bülent Eczacibasi said that the company believes the new collaboration will not only facilitate innovation but will also create added value in the field of healthcare.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Bülent Eczacibasi said: “Our target is to ensure that the important worldwide advances in the field of biotech products are simultaneously reflected and reach more people in our country, and think that Zydus is a very right partner in this regard.”

Headquartered in Ahmedabad, India, Zydus Cadila discovers and manufactures, as well as markets a wide range of healthcare therapies.

Zydus Cadila is currently marketing eight biosimilars products in India and aims at increasing patients’ access to high-quality biosimilars at affordable costs.